Tokyo Tape
Sign in
← Koa Shoji Holdings

Quarterly report · Q3

9273.TEDINET S100TEGN
Period2023-07-01 → 2024-03-31
Filed2024-05-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥16.8bn2023-07-01 → 2024-03-31Cons.Net sales
Revenue¥22.1bn2022-07-01 → 2023-06-30Cons.Net sales (5-year summary)
Revenue¥16.2bn2022-07-01 → 2023-03-31Cons.Net sales
Operating income¥3.6bn2023-07-01 → 2024-03-31Cons.Operating income
Operating income¥3.3bn2022-07-01 → 2023-03-31Cons.Operating income
Ordinary income¥3.6bn2023-07-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥4.1bn2022-07-01 → 2023-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.2bn2022-07-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥3.6bn2023-07-01 → 2024-03-31Cons.Income before income taxes
Profit before tax¥3.2bn2022-07-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.7bn2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2023-07-01 → 2024-03-31Cons.Profit loss
Net income¥2.1bn2022-07-01 → 2023-03-31Cons.Profit loss
Total assets¥30.0bnat 2024-03-31Cons.Assets
Total assets¥28.5bnat 2023-06-30Cons.Assets
Total assets¥27.5bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥7.3bnat 2024-03-31Cons.Liabilities
Total liabilities¥7.5bnat 2023-06-30Cons.Liabilities
Net assets / equity¥22.7bnat 2024-03-31Cons.Net assets
Net assets / equity¥20.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥20.3bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥10.7bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥10.8bnat 2023-06-30Cons.Cash and deposits
EPS (basic)¥57.12023-07-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.642024-01-01 → 2024-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.832022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥52.482022-07-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.292023-01-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio75.7%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio73.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio73.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-03-31−¥1.3bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-03-31−¥11m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥10.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥2.1bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2023-07-01 → 2024-03-31¥6.5bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2023-07-01 → 2024-03-31¥1.5bn
—segment totalrevenue2023-07-01 → 2024-03-31¥18.0bn
—segment totalrevenue external2023-07-01 → 2024-03-31¥16.8bn
—segment totalrevenue intersegment2023-07-01 → 2024-03-31¥1.3bn
—segment totalsegment profit2023-07-01 → 2024-03-31¥3.6bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-03-31−¥1.4bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-03-31¥16m
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥11.5bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥10.2bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
jpcrp040300-q3r_E34071-000Drug Substance Sales Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥2.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentrevenue external2022-07-01 → 2023-03-31¥6.0bn
jpcrp040300-q3r_E34071-000Pharmaceutical Marketing Businessreportable segmentsegment profit2022-07-01 → 2023-03-31¥1.2bn
—segment totalrevenue2022-07-01 → 2023-03-31¥17.5bn
—segment totalrevenue external2022-07-01 → 2023-03-31¥16.2bn
—segment totalrevenue intersegment2022-07-01 → 2023-03-31¥1.4bn
—segment totalsegment profit2022-07-01 → 2023-03-31¥3.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 356
ItemContextValueUnit
Treasury stockPrior1YearInstant-407000JPY
Treasury stockCurrentQuarterInstant-407000JPY
Shareholders equityPrior1YearInstant20899787000JPY
Shareholders equityCurrentQuarterInstant22686658000JPY
Valuation difference on available for sale securitiesPrior1YearInstant11915000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant36736000JPY
Deferred gains or losses on hedgesPrior1YearInstant11785000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-999000JPY
Valuation and translation adjustmentsPrior1YearInstant23700000JPY
Valuation and translation adjustmentsCurrentQuarterInstant35736000JPY
Net assetsPrior1YearInstant20923488000JPY
Net assetsCurrentQuarterInstant22722395000JPY
Liabilities and net assetsPrior1YearInstant28464493000JPY
Liabilities and net assetsCurrentQuarterInstant30002458000JPY
Net salesPrior1YTDDuration16159005000JPY
Net salesCurrentYTDDuration16772478000JPY
Cost of salesPrior1YTDDuration11358602000JPY
Cost of salesCurrentYTDDuration11625588000JPY
Gross profitPrior1YTDDuration4800402000JPY
Gross profitCurrentYTDDuration5146890000JPY
Selling general and administrative expensesPrior1YTDDuration1524274000JPY
Selling general and administrative expensesCurrentYTDDuration1578875000JPY
Operating incomePrior1YTDDuration3276128000JPY
Operating incomeCurrentYTDDuration3568014000JPY
Interest and dividends income noiPrior1YTDDuration1844000JPY
Interest and dividends income noiCurrentYTDDuration1950000JPY
Commission fee noiPrior1YTDDuration12436000JPY
Commission fee noiCurrentYTDDuration8049000JPY
Compensation income noiPrior1YTDDuration7162000JPY
Compensation income noiCurrentYTDDuration794000JPY
Insurance income noiPrior1YTDDuration－JPY
Insurance income noiCurrentYTDDuration26533000JPY
Other noiPrior1YTDDuration4866000JPY
Other noiCurrentYTDDuration5390000JPY
Non operating incomePrior1YTDDuration26310000JPY
Non operating incomeCurrentYTDDuration42717000JPY
Interest expenses noePrior1YTDDuration5751000JPY
Interest expenses noeCurrentYTDDuration5176000JPY
Loss on valuation of investment securities noePrior1YTDDuration3071000JPY
Loss on valuation of investment securities noeCurrentYTDDuration－JPY
Foreign exchange losses noePrior1YTDDuration55990000JPY
Foreign exchange losses noeCurrentYTDDuration17718000JPY
Commission fee noePrior1YTDDuration－JPY
Commission fee noeCurrentYTDDuration15000000JPY
Voluntary recall related expenses noePrior1YTDDuration13127000JPY
Voluntary recall related expenses noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration10606000JPY
Other noeCurrentYTDDuration766000JPY
Non operating expensesPrior1YTDDuration88546000JPY
Non operating expensesCurrentYTDDuration38661000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-07-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-07-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass